Editorial Commentary Is Resveratrol the Magic Bullet for Pulmonary Hypertension?

Pulmonary hypertension (PHTN) remains a disease withhigh morbidity and mortality and no known cure. The World Health Organization has categorized PHTN into 5 clinical classifications, as follows: (1) pulmonary artery hypertension; (2) PHTN with left heart disease; (3) PHTN with respiratory disease; (4) PHTN caused by chronic throm-botic/embolic disease; and (5) miscellaneous PHTN.1 Despite the broad and varied nature of these clinical conditions, PHTN presents with similar clinical pathological changes in the lung, including altered vasoreactivity, endothelial dysfunction, vascu-lar intimal and medial remodeling, activation of inflammatory processes, and platelet activation. If untreated, these changes lead to right heart stress, failure, and death.1 At the cellular level, enhanced vasoconstriction, endothelial dysfunction, and endo-thelial cell and vascular smooth muscle cell (VSMC) prolifera-tion are key components of disease progression. This underlyin